ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

ClinicalTrials.gov ID: NCT06037252

Public ClinicalTrials.gov record NCT06037252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity

Study identification

NCT ID
NCT06037252
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
414 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Tirzepatide Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 20, 2023
Primary completion
Jan 7, 2026
Completion
Sep 30, 2026
Last update posted
Mar 22, 2026

2023 – 2026

United States locations

U.S. sites
20
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
Medical Advancement Centers of Arizona Phoenix Arizona 85044
John Muir Physician Network Research Center Concord California 94520
Care Access - Sacramento Sacramento California 95831
Care Access - Aurora Aurora Colorado 80012
Chase Medical Research, LLC Waterbury Connecticut 06708
Retreat Medical Research Miami Florida 33135
American Research Centers of Florida Pembroke Pines Florida 33027
Alta Pharmaceutical Research Center Norcross Georgia 30092
AGILE Clinical Research Trials, LLC Sandy Springs Georgia 30328
Northwestern University Chicago Illinois 60611
Qualmedica Research, LLC Evansville Indiana 47715
Integrated Clinical Trial Services, Inc. West Des Moines Iowa 50265
Accellacare - Wilmington - 1917 Tradd Court Wilmington North Carolina 28401
Velocity Clinical Research, Mt. Auburn Cincinnati Ohio 45219
Summit Headlands Portland Oregon 97210
Clinical Research Associates Inc Nashville Tennessee 37203
Juno Research Houston Texas 77040
Southern Endocrinology Associates Mesquite Texas 75149
Charlottesville Medical Research Charlottesville Virginia 22911
Northwest Clinical Research Center Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06037252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06037252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →